Beyond FDA: Peer-Reviewed Validation Predicts DTx Survival

The thrill of getting FDA clearance often blinds people to the brutal reality of getting paid in digital health. For any of us in early-stage healthcare VC or risk analysis, understanding the chasm between FDA authorization and sustainable reimbursement is everything. The trajectory of the first prescription digital therapeutic (PDT) pioneers is a blunt cautionary tale, proving that a rock-solid scientific foundation, validated by peer-reviewed clinical outcomes and cemented by payer contracts, is the only real defense against market failure.

The Illusion of FDA Clearance Without Payer Alignment

The story for most digital therapeutics used to start with a big win: FDA clearance, usually through the De Novo pathway for new, low-risk devices. That regulatory stamp got investors excited, signaling the product was safe and effective enough for clinical use. But the commercial graveyard is full of products that hit that regulatory mark and then died waiting for scalable reimbursement. The real work is convincing payers that your clinical benefit creates economic value they’re willing to cover. The Centers for Medicare and Medicaid Services (CMS) is the 800-pound gorilla here, setting the reimbursement benchmarks everyone else watches. While CMS is slowly creating billing codes, like the three new Healthcare Common Procedure Coding System (HCPCS) codes (G0552, G0553, and G0554) for digital mental health coming online January 1, 2025, or the 2026 expansion for ADHD, the process is a slog. An FDA clearance is just table stakes. The true test is showing your SaMD has real-world utility that a payer’s benefit manager understands and that fits into a doctor’s day without a ton of friction. Without that, you won’t build a sustainable revenue model.

Commercial Trajectories: Pear Therapeutics and Akili Interactive

The cases of Pear Therapeutics and Akili Interactive show you exactly how complex the digital therapeutics market is.

Pear Therapeutics: A Pioneering Collapse

Pear Therapeutics led the charge. They were the trailblazers with FDA-cleared prescription digital therapeutics like reSET and reSET-O for substance use disorder and Somryst for chronic insomnia, securing De Novo classifications that drew a ton of investment. But despite all the regulatory wins, they couldn’t get broad adoption or consistent payment. Their business model was a classic pharma sales approach, which just didn’t work for this new category. Payers didn’t have policies for PDTs, and providers found them hard to fit into their workflows. Pear’s collapse and eventual asset liquidation proves that regulatory success means nothing without commercial viability. They couldn’t get enough payers to sign long-term contracts or figure out a scalable distribution plan, and that’s what killed them. The fact that their assets sold for a mere $6.05 million tells you everything you need to know about the gap between their valuation hype and actual commercial worth, a painful lesson for any healthcare AI venture capital firm. Pear Therapeutics bankruptcy filing details

Akili Interactive: Adjusting to Market Realities

Akili Interactive, the company behind EndeavorRx, the first FDA-cleared video game treatment for ADHD in children, ran into the same reimbursement walls. EndeavorRx also got a De Novo classification, another big regulatory achievement. Akili first tried a prescription model just like Pear, but getting payers on board and managing prescriptions for a digital product was a nightmare. So they changed their plan. Recognizing the barriers weren’t going away soon, Akili shifted to a non-prescription model. They launched EndeavorOTC for adults in June 2023 under an FDA enforcement policy, then got full FDA clearance for it as an over-the-counter digital treatment for adults with ADHD in June 2024. Akili also announced plans to submit data to the FDA in 2024 to convert its pediatric prescription product, EndeavorRx, to an over-the-counter treatment. This pivot meant giving up the higher price of a prescription, but it opened up direct access for consumers and simplified purchasing. It’s a pragmatic move when the traditional payer system isn’t ready for you. Their subsequent acquisition by Virtual Therapeutics for approximately $34 million in 2024 shows how an adaptable commercial strategy can find a path forward, even when reimbursement is a mess.

The Indispensable Role of Peer-Reviewed Clinical Validation

The implosion at Pear and the pivot at Akili both point to the same thing: clinical validation that goes far beyond the FDA’s requirements is absolutely non-negotiable for survival. For any early-stage digital health investor, you have to look past the FDA’s green light and dig into the quality and generalizability of the actual clinical evidence. It’s the only thing that matters in the long run.

Beyond Efficacy: Real-World Effectiveness and Economic Value

FDA clearance just confirms efficacy in a controlled trial. Payers need proof of real-world effectiveness and, most importantly, economic value. What does that mean in practice? * Large-scale, diverse clinical trials: You need studies that look like the actual patient population where the therapeutic will be used, not just a hand-picked, ideal group.

• Meaningful clinical outcomes: Show you can actually change the course of a disease, cut down on healthcare use, or seriously improve quality of life.
• Health economic outcomes research (HEOR): This is the hard data that shows your digital therapeutic saves money compared to the current standard of care, fewer hospitalizations, ER visits, or lower medication costs. Following established ISPOR guidelines for HEOR studies is a good start.
• Durability of effect: The benefits have to stick around long enough to justify paying for your product month after month. Companies that get their outcomes published in high-impact, peer-reviewed journals have a much better shot at durable funding. You have to prove your product works in a way that saves money or significantly improves lives for a large population, and does so reliably. That evidence becomes your “data moat” against competitors and the foundation for every payer conversation.
  

  Due Diligence Checklist for Clinical and Reimbursement Validation

When VCs and risk analysts are doing diligence on a healthcare AI venture capital opportunity, the clinical and reimbursement strategy needs the same intense scrutiny as the tech itself. 1. Clinical Evidence Quality:

• Trial Design: Are the studies well-designed, randomized, controlled, and powered correctly? And do they actually use patient populations that reflect the real world? * Endpoints: Are the primary and secondary endpoints clinically meaningful and tied to things payers care about (e.g., reduction in hospitalizations, improved functional status, validated symptom scores)? * Publication Record: Is the data published in reputable, peer-reviewed journals, and what is their impact factor? * Longitudinal Data: Is there proof of sustained efficacy and engagement over extended periods? * RWE Strategy: The company must have a clear plan for collecting and using Real-World Evidence (RWE) post-launch to strengthen its case with payers and for post-market surveillance. 2. Reimbursement Strategy and Payer Engagement:
• Payer Contract Status: How many commercial payer contracts are signed, and what’s their real scope and duration? * Reimbursement Codes: Has the company locked down the right CPT codes (Category I or III)? You also need to know the status of relevant CMS billing code updates, especially the new HCPCS codes G0552, G0553, and G0554 hitting in 2025 and the ADHD digital therapeutics expansion for 2026. This is where CMS national coverage determinations for digital health come into play.
• Value Proposition: The economic value proposition needs to be sharp and backed by solid HEOR data.
• Sales Model: Is the commercial model, whether it’s direct-to-payer, provider-focused, a hybrid, or OTC, actually realistic for the current reimbursement environment? * Payer Policy Development: The team should be actively talking with payers to help write the coverage policies for their own intervention. 3. Regulatory Strategy Beyond Clearance:
• PCCP Development: For any AI/ML-driven SaMD, check for a clear Predetermined Change Control Plan (PCCP) that’s been agreed to with the FDA. This lets them improve the model without going back for a full re-submission every time.
• GMLP Adherence: Good Machine Learning Practice (GMLP) principles need to be baked into how the product is built and maintained. GMLP compliance should be a standard diligence inquiry.
• QMS/ISO 13485: A serious company will have a strong Quality Management System (QMS) in place, and ISO 13485 certification is a clear signal that they’re ready to scale and even expand internationally.
  

  Conclusion

The digital health market, especially for AI-driven solutions, is growing up. The initial hype around getting FDA clearance has been replaced by the hard-headed math of commercial reality. The stories of Pear Therapeutics and Akili Interactive are clear: market survival for digital therapeutics depends entirely on mastering the reimbursement game. For investors, that means scrutinizing the clinical validation for real-world effectiveness, economic value, and the durability of payer contracts. The companies that win will be the ones that can prove the science, translating strong clinical data into real value for patients and payers. Our ongoing digital health funding rounds tracker will keep showing how this alignment of science and reimbursement affects funding durability and exit multiples in the evolving healthcare AI venture capital field.